A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
Purpose
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
Condition
- Type 1 Diabetes
Eligibility
- Eligible Ages
- Between 18 Years and 65 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
Clinical history of T1D with greater than or equal to (>=) 5 years duration Participant is on a stable diabetic treatment Consistent use of continuous glucose monitoring (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study
Exclusion Criteria
Prior islet cell transplant, organ transplant, or cell therapy
Study Design
- Phase
- Phase 1/Phase 2
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental VX-264 |
|
Recruiting Locations
More Details
- NCT ID
- NCT05791201
- Status
- Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals Incorporated